Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
Autor: | Christoph Sarrazin, Stefan Zeuzem, Johannes Vermehren, Simone Susser, D. Perner, Annemarie Berger, Kai-Henrik Peiffer, Regina Allwinn |
---|---|
Rok vydání: | 2012 |
Předmět: |
Adult
Male medicine.medical_specialty Genotype Hepatitis C virus Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Virus Polyethylene Glycols chemistry.chemical_compound Predictive Value of Tests Virology Internal medicine Ribavirin BDNA test Humans Medicine Aged Immunoassay business.industry Viral Core Proteins Interferon-alpha virus diseases Hepatitis C Hepatitis C Chronic Middle Aged Abbott Diagnostics medicine.disease Recombinant Proteins digestive system diseases Infectious Diseases chemistry Predictive value of tests Immunology RNA Viral Female Drug Monitoring Hepatitis C Antigens business |
Zdroj: | Journal of Clinical Virology. 55:17-22 |
ISSN: | 1386-6532 |
DOI: | 10.1016/j.jcv.2012.05.008 |
Popis: | Virologic response-monitoring is essential for determining therapy duration in patients with chronic hepatitis C virus (HCV) infection. This is usually performed using highly sensitive HCV-RNA assays. However, HCV-RNA assays are time-consuming, expensive and require highly trained personnel. Quantitative determination of HCV core-antigen (HCVAg) levels may be used to supplement treatment monitoring.The clinical utility of the ARCHITECT HCV Ag assay (Abbott Diagnostics) for response-guided therapy was investigated.We analyzed serum from 160 patients with HCV genotype 1 infection who had been treated with peg-interferon alfa-2b/ribavirin. HCVAg levels were determined at baseline, weeks 1, 2, 4 and 12. HCVAg levels were compared to those obtained with HCV-RNA assays: VERSANT HCV Quantitative 3.0 (bDNA) and Qualitative (TMA, both Siemens Healthcare) assay and the Abbott RealTime HCV assay (ART; Abbott Diagnostics).Baseline HCVAg levels correlated well with HCV-RNA as assessed by bDNA (r=0.91; p0.0001) and ART (r=0.92; p0.0001), respectively. Patients with undetectable HCVAg levels at week 1 had a 90.9% probability (positive predictive value) to achieve a rapid virologic response (HCV-RNA undetectable at week 4) based on TMA and 86.4% based on ART, respectively. Patients with less than 1 log(10) reduction in HCVAg between baseline and week 12 had a 90% probability (negative predictive value) to achieve a nonresponse (2 log(10) decline in HCV-RNA between baseline and week 12) based on bDNA and 100% based on ART, respectively.Determination of HCVAg may be useful for antiviral response-monitoring in patients with HCV genotype 1 infection. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.